All GeoVax Labs Articles
GeoVax Secures Patent for Groundbreaking Malaria Vaccine Platform – ( $GOVX $IBB $XBI )
In a move that both underlines scientific ingenuity and bolsters global health ambitions, GeoVax Labs, Inc. (GOVX) has announced the issuance of U.S. Patent No. 12,329,808, a milestone that covers a novel vaccine construct designed to prevent malaria infection. This patent, granted from applicat...
Jun 25, 2025
View Article
GeoVax Applauds FDA’s Green Light for Keytruda: A New Chapter in Head and Neck Cancer—and a Wink at Gedeptin’s Future – ( $GOVX $MRK $XBI )
In the ever-evolving world of oncology, every so often a regulatory decision comes along that feels less like a footnote and more like a new chapter. The U.S. Food and Drug Administration’s (FDA) recent approval of Merck’s (MRK) Keytruda® (pembrolizumab) for resectable, locally advanced hea...
Jun 24, 2025
View Article
GeoVax Labs: A Shot in the Arm for Global Health, with a European Twist – ( $GOVX $IBB $XBI )
In a world where vaccine innovation can sometimes feel like a slow-motion sprint, GeoVax Labs, Inc. (NASDAQ: GOVX) has just received a welcome boost—this time, courtesy of European regulators. The company, known for its nimble approach to tackling some of the world’s most persistent health threa...
Jun 18, 2025
View Article
Stay Informed. Stay Competitive.
Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.
We value your privacy and will never share your information.
